Pfizer to buy Anacor for $4.5 billion

The deal, valued at $5.2 billion including debt, is expected to close in third quarter.

Getty Images

By

AnneSteele

Pfizer Inc. said Monday it would buy Anacor Pharmaceuticals Inc. in an all-cash deal worth about $4.5 billion, as it turns to smaller deals after walking away from its scuttled acquisition of Allergan PLC.

Pfizer
PFE, -0.69%
will acquire drugmaker Anacor
US:ANAC
for $99.25 a share, a 55% premium to Friday’s closing price. The companies said the deal, including debt, is valued at $5.2 billion.

Graphic embed is no longer available.

On Monday, the companies said Palo Alto-based Anacor will be a “strong fit” with New York-based Pfizer’s inflammation and immunology portfolio. Anacor has no products on the market, but its flagship asset, crisaborole, is currently under review by the U.S. Food and Drug Administration for the treatment of eczema.

Pfizer said the transaction, which is expected to close in the third quarter, will not impact its guidance for the year.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.